InvestorsHub Logo
Followers 20
Posts 1631
Boards Moderated 0
Alias Born 11/10/2010

Re: None

Monday, 03/27/2017 9:01:57 AM

Monday, March 27, 2017 9:01:57 AM

Post# of 592
FDA Grants Priority Review for Eagle Pharmaceuticals’ Ryanodex NDA for the Treatment of Exertional Heat Stroke

http://investor.eagleus.com/press-release/fda-grants-priority-review-eagle-pharmaceuticals-ryanodex-nda-treatment-exertional-hea

Under the Prescription Drug User Fee Act (PDUFA), the FDA will aim to complete its review within six months of the NDA submission; the PDUFA date for the NDA has been set for July 23, 2017.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EGRX News